Fig. 3: Assessment of miR-493-5p expression and MEG3-DMR methylation in clinical samples from HCC patients. | Cell Death & Disease

Fig. 3: Assessment of miR-493-5p expression and MEG3-DMR methylation in clinical samples from HCC patients.

From: MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells

Fig. 3

a Expression levels of miR-493-5p in clinical samples. The boxplots illustrate differential gene expression in 18 primary HCC tumors (T) compared with their corresponding non-tumor tissues (NT). Mann–Whitney U test was used to calculate the p-value. b Comparison of miR-493-5p expression between moderate and advanced liver cancer. Tumors with a size superior or equal to 5 cm were considered advanced HCC tumors. Mann–Whitney U test indicated a significant decrease in the miR-493-5p level in the group of patients with advanced tumors (p < 0.05). c Scatter plots of Spearman’s correlation coefficient analysis between miR-493-5p and MEG3 relative expression, measured by RT-qPCR in HCC tumor tissues (n = 18). d Comparison of MEG3-DMR methylation levels between moderate and advanced liver cancer. Methylation levels of four CpG sites (Region 1) were randomly evaluated via COBRA in advanced (n = 5) and moderate tumors (n = 3). Histograms show the mean ± SD. Significance is indicated as *p < 0.05 and **p < 0.01 (t-test). e Correlation analysis between miR-493-5p expression and MEG3-DMR methylation levels in HCC tumors (Spearman’s rank coefficient). The red and blue plots show advanced tumors and moderate tumors, respectively

Back to article page